Pharmaceuticals

Purple Biotech

Purple Biotech released FY2025 9 Months earnings on November 14 EST, actual revenue USD 0, actual EPS USD -0.8544

Purple Biotech released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -0.286

Purple Biotech released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 0, actual EPS USD -0.3964

Purple Biotech released FY2025 Semi-Annual Earnings on August 6, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.5728

Purple Biotech Ltd. Reveals New Preclinical Data

Purple Biotech Launches NT219 Phase II Clinical Study

Purple Biotech released FY2025 Q1 earnings on May 21 (EST), actual revenue USD 0, actual EPS USD -0.172

Purple Biotech Reports Positive Financial Results and Reveals CM24 Study Data

Purple Biotech Reports Q1 2025 Net Loss Narrowing to $500,000

Purple Biotech Ltd. Discloses New Data on NT219

Purple Biotech released FY2024 annual earnings on March 10 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -4.4158 USD (forecast -19.2 USD)

Purple Biotech released FY2024 Q4 earnings on March 10 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.1998 USD (forecast -5 USD)

Purple Biotech released FY2024 Q3 earnings on November 15 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.3826 USD (forecast -4.8 USD)

Purple Biotech released FY2024 9 Months Earnings on November 15 (EST), with actual revenue of 0 USD and EPS of -4.9046 USD

Purple Biotech Ltd. Reports Positive Biomarker Results for CM24 at AACR Conference

Purple Biotech Releases Q2 2024 Earnings Report, EPS Exceeds Expectations

Zhi Biological Technology Releases Positive Results of CM24 Pancreatic Cancer Phase II Clinical Study

Purple Biotech Releases Positive Interim Phase 2 Data for CM24 in Pancreatic Cancer at 2024 ASCO Meeting

Purple Biotech released FY2023 annual earnings on March 5 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -18 USD (forecast -18.4 USD)

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap